Development of a p38δ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor
Márcia Goettert1, Nouran Shaalan, Ralph Graeser
1Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls University of Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
Abstract:
The p38 mitogen activated protein kinase (MAPK) has emerged as a target for treating inflammatory diseases, like rheumatoid arthritis (RA). Expression of p38δ is induced in rheumatoid arthritis synovial fibroblasts (RASFs) by a cytokine-independent pathway substantially different from other MAPK pathways. To identify inhibitors of p38δ MAPK, we developed a direct ELISA assay based on a previously described p38α assay for monitoring the phosphorylation of ATF-2. This work presents a straightforward assay for evaluating the potency of small-molecule inhibitors. To validate the assay under optimized conditions, we used reference compounds and achieved results comparable to published data.
Insights
Researchers developed a new assay to find drugs targeting p38δ MAPK, a key player in inflammatory diseases like rheumatoid arthritis. This method helps evaluate small-molecule inhibitors for potential treatments.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- p38 mitogen-activated protein kinase (MAPK) is a therapeutic target for inflammatory conditions such as rheumatoid arthritis (RA).
- p38δ MAPK expression in rheumatoid arthritis synovial fibroblasts (RASFs) is upregulated via a cytokine-independent pathway, distinct from other MAPK pathways.
- Identifying specific inhibitors for p38δ MAPK is crucial for developing novel RA treatments.
Purpose of the Study:
- To develop a direct ELISA assay for identifying and evaluating small-molecule inhibitors of p38δ MAPK.
- To establish a robust method for monitoring the phosphorylation of ATF-2, a downstream target of p38δ MAPK.
- To validate the assay's performance using known reference compounds.
Main Methods:
- A direct enzyme-linked immunosorbent assay (ELISA) was adapted from a p38α assay.
- The assay monitors the phosphorylation of Activating Transcription Factor 2 (ATF-2) as a readout for p38δ MAPK activity.
- Assay optimization and validation were performed using established reference compounds.
Main Results:
- A straightforward and effective ELISA assay for p38δ MAPK activity was successfully developed.
- The assay demonstrated reliable performance in evaluating the potency of small-molecule inhibitors.
- Validation results using reference compounds were comparable to previously published data, confirming assay accuracy.
Conclusions:
- The developed ELISA assay provides a valuable tool for screening and characterizing p38δ MAPK inhibitors.
- This assay facilitates the discovery of new therapeutic agents for inflammatory diseases, particularly rheumatoid arthritis.
- The findings support the potential of targeting p38δ MAPK in drug development for RA.
